The 3rd Annual Meeting of the International Academy for Clinical Hematology IACH: Focus on Leukemia, October 1-3, 2020, saw the discussion of key updates in the hemonc field with a focus on leukemia.

Highlights from this year’s IACH Annual Meeting include management of elderly leukemia, CAR T-cell therapy, rare leukemias as well as novel drugs.

View all videos

IACH Focus on Leukemia 2020

01–03 October 2020 | Nice, France

We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies:

🎥: http://ow.ly/GGiK50KVRjM

#MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022

We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks.

@SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm

#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more.

Visit http://VJHemOnc.com for our interviews from this year's meeting!

#SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm

At #SOHO22: Our Dr. Robert Orlowski discusses early data in bispecific T cell engagement for treatment of multiple myeloma. @Myeloma_Doc #EndCancer

Load More...

IACH Focus on Leukemia 2020

01–03 October 2020 | Nice, France

The 3rd Annual Meeting of the International Academy for Clinical Hematology IACH: Focus on Leukemia, October 1-3, 2020, saw the discussion of key updates in the hemonc field with a focus on leukemia.

Highlights from this year’s IACH Annual Meeting include management of elderly leukemia, CAR T-cell therapy, rare leukemias as well as novel drugs.

View all videos

We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies:

🎥: http://ow.ly/GGiK50KVRjM

#MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022

We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks.

@SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm

#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more.

Visit http://VJHemOnc.com for our interviews from this year's meeting!

#SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm

At #SOHO22: Our Dr. Robert Orlowski discusses early data in bispecific T cell engagement for treatment of multiple myeloma. @Myeloma_Doc #EndCancer

Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter